Oppenheimer Maintains Gossamer Bio(GOSS.US) With Buy Rating, Raises Target Price to $9
Gossamer Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Goldman Sachs Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $8
Buy Rating Affirmed for Gossamer Bio Amidst Financial Growth and Clinical Advancements
Barclays Reaffirms Their Hold Rating on Gossamer Bio (GOSS)
Gossamer Bio Analyst Ratings
Piper Sandler Keeps Their Buy Rating on Gossamer Bio (GOSS)
Analysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX), Spruce Biosciences (SPRB) and Gossamer Bio (GOSS)
Gossamer Bio (GOSS) Receives a Buy From Piper Sandler
Gossamer Bio Analyst Ratings
Gossamer Bio Analyst Ratings
Buy Rating Reaffirmed for Gossamer Bio on Seralutinib's Promising Clinical Data and Future Prospects
Gossamer Bio Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target
Buy Rating Affirmed for Gossamer Bio Amidst Strategic Collaboration and Market Opportunity Growth
Gossamer Bio Analyst Ratings
Wedbush Reiterates Outperform on Gossamer Bio, Maintains $4 Price Target
Strategic Partnership and Financial Upside: Gossamer Bio Earns a Buy Rating
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS), RxSight (RXST) and Edwards Lifesciences (EW)
Buy Rating on Gossamer Bio Supported by Strategic Partnership and Market Underestimation
No Data
No Data